Tafamidis meglumine comment watch save

  • TRADE NAME: Vyndaqel (FoldRx Pharmaceuticals)
  • INDICATIONS: Cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults. Transthyretin familial amyloid polyneuropathy (TTR-FAP).
  • CLASS: Transthyretin stabilizer
  • HALF-LIFE: 49 hours
  • FDA APPROVAL DATE: 05/03/2019
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Breast Cancer Resistance Protein inhibitors, Imatinib, Methotrexate, Rosuvastatin
  • PREGNANCY: Based on findings from animal studies, tafamidis may cause fetal harm when administered to a pregnant woman.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top